Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer

Journal article

Peer reviewed

Clinical lung cancer, Vol.7(2), pp.89-91

2005-09

PMID: 16179094

Abstract

Lung Neoplasms - drug therapy

Taxoids - therapeutic use

Antineoplastic Combined Chemotherapy Protocols - therapeutic use

Piperidines - therapeutic use

Protein Kinase Inhibitors - therapeutic use

Quinazolines - therapeutic use

Humans

Receptor, Epidermal Growth Factor - drug effects

Receptors, Vascular Endothelial Growth Factor - drug effects

Antineoplastic Agents - therapeutic use

Carcinoma, Non-Small-Cell Lung - drug therapy

Clinical Trials, Phase II as Topic

5 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics: 1 Clinical & Life Sciences; 1.199 Lung Cancer; 1.199.581 NSCLC
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer
Creators: David Lee
Publication Details: Clinical lung cancer, Vol.7(2), pp.89-91
Academic Unit: Miller School of Medicine; UMMG Department of Public Health Sciences Research
Language: English
Resource Type: Journal article
PMID: 16179094
Record Identifier: 991031599022802976